CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 938,677 | $16,914,960 | 9.38% |
| Finepoint Capital LP | 797,527 | $14,371,437 | 4.97% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $41,546,155 | 4.28% |
| 5AM Venture Management, LLC | 862,286 | $15,538,394 | 3.87% |
| Opaleye Management Inc. | 845,000 | $15,226,900 | 3.64% |
| First Light Asset Management, LLC | 1,557,222 | $28,061,140 | 2.20% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,540,820 | 2.18% |
| Paradigm Biocapital Advisors LP | 1,395,002 | $25,137,936 | 1.94% |
| Altium Capital Management LP | 135,000 | $2,432,700 | 1.84% |
| MPM BioImpact LLC | 479,053 | $8,632,535 | 1.74% |
| Novo Holdings A/S | 1,100,000 | $19,822,000 | 1.53% |
| Frazier Life Sciences Management, L.P. | 1,414,823 | $25,495,110 | 1.52% |
| Ikarian Capital, LLC | 475,000 | $8,559,501 | 1.36% |
| Orbimed Advisors | 3,950,796 | $71,193,344 | 1.29% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 5,298,088 | $95,471,546 | 1.20% |
| Perceptive Advisors | 1,946,937 | $35,083,805 | 1.02% |
| EcoR1 Capital, LLC | 1,330,263 | $23,971,339 | 0.59% |
| AlphaCentric Advisors LLC | 47,000 | $846,940 | 0.47% |
| BRAIDWELL LP | 650,312 | $11,718,622 | 0.38% |
| Connacht Asset Management LP | 12,406 | $223,556 | 0.31% |
External links
This page lists CRINETICS PHARMACEUTICALS IN's shareholders in Q2 2023. To view CRINETICS PHARMACEUTICALS IN's shareholder history, click here.